Research programme: drug discovery - Boehringer Ingelheim/Morphochem
Latest Information Update: 22 Jul 2010
At a glance
- Originator Boehringer Ingelheim; Morphochem AG
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
- 04 Feb 2004 Preclinical trials in Undefined in Germany (unspecified route)